Drug Type Antibody drug conjugate (ADC), Biosimilar |
Synonyms 恩美曲妥珠单抗生物类似药(Defence), ACCUADC 001, ACCUADC-001 + [1] |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC35H48ClN3O10S |
InChIKeyANZJBCHSOXCCRQ-FKUXLPTCSA-N |
CAS Registry139504-50-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stomach Cancer | Preclinical | Canada | 01 Dec 2021 | |
Breast Cancer | Preclinical | - | - |